| Literature DB >> 25106673 |
Ting Xia1, David G Wilder, Maruti R Gudavalli, James W DeVocht, Robert D Vining, Katherine A Pohlman, Gregory N Kawchuk, Cynthia R Long, Christine M Goertz.
Abstract
BACKGROUND: Low back pain (LBP) is a major health issue due to its high prevalence rate and socioeconomic cost. While spinal manipulation (SM) is recommended for LBP treatment by recently published clinical guidelines, the underlying therapeutic mechanisms remain unclear. Spinal stiffness is routinely examined and used in clinical decisions for SM delivery. It has also been explored as a predictor for clinical improvement. Flexion-relaxation phenomenon has been demonstrated to distinguish between LBP and healthy populations. The primary objective of the current study is to collect preliminary estimates of variability and effect size for the associations of these two physiological measures with patient-centered outcomes in chronic LBP patients. Additionally biomechanical characteristics of SM delivery are collected with the intention to explore the potential dose-response relationship between SM and LBP improvement. METHODS/Entities:
Mesh:
Year: 2014 PMID: 25106673 PMCID: PMC4139615 DOI: 10.1186/1472-6882-14-292
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Study inclusion and exclusion criteria
| Inclusion criteria | Rationale | Source |
|---|---|---|
| Age ≥ 21 and ≤ 65 | Chronic LBP not as common under age 21. Older adults not as likely to tolerate biomechanical tests | PS, BL1 |
| Chronic low back pain matching QTF Classifications 1, 2, and 3 | Low back pain, uncomplicated by known nerve root compression, neurological signs or prior surgery | CR |
| RMDQ ≥ 6 | Disability high enough to prevent floor effect | PS |
| NRS Pain (Average within past 24 hours) ≥ 2 at PS and BL1 and BL2, and ≥ 4 at PS or BL1 | Pain high enough to prevent floor effect | PS, BL1, BL2 |
|
| ||
| Additional diagnostic tests or urgent/emergent procedures needed beyond study exam procedures | Advanced diagnostic tests or other necessary evaluation(s) are outside study scope | CR |
| BMI ≥ 40 | Unable to adequately perform manipulation procedures per study protocol | BL1 |
| BDI II score ≥ 29 | May interfere with protocol compliance and data collection | BL1 |
| Compliance concerns | May compromise ability to comply with study protocols | CR |
| Co-morbidity requiring coincident clinical management | May interfere with study requirements, pose significant scheduling burden, or pose a safety risk | CR |
| Inability to read or verbally comprehend English | Proxy unavailable | BL1 |
| Inflammatory or destructive tissue changes to the spine | Potential intolerance to biomechanical testing or treatment protocols | PS, CR |
| Joint replacement history | Potential intolerance to biomechanical testing or treatment protocols | PS, CR |
| Moving from area within 8 weeks | May interfere with ability to comply with study protocol | PS, BL1, BL2 |
| Neuromuscular disease | Interference with biomechanical measurements | PS |
| No indication for SM at L1 – L5 or sacroiliac joint (s) | Spinal Manipulation is only treatment available | CR |
| Open or pending litigation for LBP or seeking/receiving disability compensation | May interfere with study compliance or data collection | PS, BL1 |
| Pacemaker/Defibrillator | Safety due to potential electromagnetic fields produced by biomechanical testing equipment | PS, BL1 |
| Peripheral arterial disease | Potential intolerance to biomechanical tests, potential need for referral, and interference with pain and disability measures | PS, CR |
| Pregnancy | Safety for biomechanical testing and may interfere with data collection | PS, BL1 |
| QTF classification 4-11 | Conditions sufficiently complicated to cause intolerance to biomechanical testing procedures or data collection | CR |
| Received SM within past 4 weeks | May interfere with data interpretation | BL1 |
| Safety | Precaution for condition(s) posing a safety risk or intolerance for treatment or biomechanical tests (i.e., excessive bruising/bleeding and adhesive sensitivity) | CR |
| Suspicion of drug or alcohol abuse | May interfere with data collection, ability to comply with study protocol, and require referral | CR |
| Uncontrolled hypertension | May interfere with study protocols and require referral | CR |
BDI-II: Beck Depression Inventory; BL1: Baseline Visit 1; BL2: Baseline Visit 2; BMI: body mass index; CR: Case Review; L1 – L5: lumbar segment level 1 to 5. LBP: low back pain; NRS: numerical rating scale; PS: Phone Screen; QTF- Quebec Task Force; SM: Spinal Manipulation.
Summary of clinical activities in the visit-by-visit basis
| Visit | Activities | |
|---|---|---|
| Screening | Phone screen | Computer‒assisted telephone interview |
| Baseline visit 1 | Informed consent document | |
| Study flow chart | ||
| Study procedure video | ||
| HIPAA | ||
| Patient-centered outcomes | ||
| Past medical history | ||
| Medication checklist | ||
| Demographics & Vital signs | ||
| Examination | ||
| X-ray & Urinalysis, if indicated | ||
| Case review | ||
| Baseline visit 2 | Report of findings, enroll | |
| Treatment | Treatment visit 1 | Pre-treatment Pain in VAS |
| Physiological assessments | ||
| Treatment-full kinetics | ||
| Physiological assessments | ||
| Post-treatment pain in VAS | ||
| Treatment visit 2 | Pre-treatment pain in VAS | |
| Treatment | ||
| Post-treatment pain in VAS | ||
| Treatment visit 3 | Pre-treatment pain in VAS | |
| Treatment-simple kinetics | ||
| Post-treatment pain in VAS | ||
| Treatment visit 4 | Same as treatment visit 2 | |
| Treatment visit 5 | Same as treatment visit 1 | |
| Treatment visit 6 | Patient-centered outcomes | |
| Pre-treatment pain in VAS | ||
| Treatment | ||
| Post-treatment pain in VAS | ||
| Treatment visits 7-8 | Same as treatment visit 2 | |
| Treatment visit 9 | Same as treatment visit 3 | |
| Treatment visits 10-11 | Same as treatment visit 2 | |
| Treatment visit 12 | Same as treatment visit 1 | |
| Exit interview | Treatment visit 13 (Final) | Patient-centered outcomes |
| Satisfaction questionnaire | ||
| Exit interview |
HIPAA: Health Insurance Portability and Accountability Act; VAS: visual analog scale.
Figure 1Illustration of spinal stiffness assessment tests. Skin marks over bony landmarks of the T11-L5 spinous processes and posterior superior iliac spine (A), palpatory stiffness assessment (B), stiffness assessment with a hand-held device (C); and stiffness assessment with an automated device (D).
Figure 2Illustration of EMG electrode placement (A) and example EMG and motion signals (B). Root-mean-square (RMS) EMG data and motion data are scaled according to the maximum of RMS EMG data (B). B contains 3 cycles of flexion (B1), holding in position while fully flexed (B2), and extension (B3).
Figure 3Self-reported record for high velocity, low amplitude spinal manipulation. Level: the segment over which the manual contact occurs (L1-5, sacrum, and sacroiliac joint); Side Up: side of body contacted by clinician providing trunk twist motion direction; Contact Point: manual contact of the thrusting hand; SP: spinous process; MP: mammillary process; DW: interspinous space 1 cm lateral to spinous processes; PSIS: posterior superior iliac spine; Ischial Tubes: Ischial tuberosity; Fossa: midpoint between ischial tuberosity and PSIS; Base: Medial aspect of the superior sacrum; Apex: inferior sacrum; Ala: sacral ala or lateral superior sacrum; Direction of thrust: direction of thrust applied by the thrusting hand; A: anterior; S: superior; I: inferior; M: medial; L: lateral.
Figure 4Illustration of segmental load assessment during side-lying high-velocity spinal manipulation.
Figure 5Putative effects of low back pain (A) and spinal manipulation (B).